Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

World's largest Takayasu's registry launches to unlock disease secrets

NCT ID NCT07558382

Knowledge-focused Sponsor: Marmara University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This global registry is collecting information from 1,000 people with Takayasu's arteritis, a rare disease that inflames and narrows large arteries. Researchers will analyze patients' symptoms, lab results, imaging, and treatments to see how the disease behaves and is managed around the world. The study does not test any new drug or procedure—it simply observes and records what happens in routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could help doctors worldwide better understand and manage Takayasu's arteritis, leading to improved diagnosis and treatment guidelines.
What could go wrong
This is an observational study, not a treatment trial. It collects existing data and does not test any new therapy, so it cannot directly lead to a cure or new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged \>18 years diagnosed with Takayasu arteritis according to ACR 1990 or ACR/EULAR 2021 criteria will be included

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Each patient must fullfill the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis. * Patients (or legally acceptable representatives of subjects enrolled) have to * provide informed and free agreement to participate in the study and to disclose any medical event to the investigator. The parents or legally acceptable representative and the adolescent subject must be willing and able to comply with the study protocol requirements for the duration of the study * freely sign written and dated informed consent after being duly informed of the nature, significance, and implications of the study; * be informed that the patient enrolled may withdraw consent at any time without prejudice to future medical care. Exclusion Criteria: Patients must be excluded from the study when the following criteria are observed: * The patient does not full-fill the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis * informed consent/assent is not provided and signed

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Takayasu arteritis (TAK) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Takayasu arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Takayasu arteritis (TAK) Takayasu's arteritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Marmara University School of Medicine

    RECRUITING

    Istanbul, Istanbul, 34899, Turkey (Türkiye)

  • Marmara University School of Medicine

    RECRUITING

    Istanbul, Istanbul, 34899, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.